Bivalirudin for Patients with Acute Coronary Syndromes

Autor: Stone, Gregg W, McLaurin, Brent T, Cox, David A, Bertrand, Michel E, Lincoff, A Michael, Moses, Jeffrey W, White, Harvey D, Pocock, Stuart J, Ware, James H, Feit, Frederick, Colombo, Antonio, Aylward, Philip E, Cequier, Angel R, Darius, Harald, Desmet, Walter, Ebrahimi, Ramin, Hamon, Martial, Rasmussen, Lars H, Rupprecht, Hans-Jürgen, Hoekstra, James, Mehran, Roxana, Ohman, E Magnus, ACUITY Investigators

Publikováno v: Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Stone, G W, McLaurin, B T, Cox, D A, Bertrand, M E, Lincoff, A M, Moses, J W, White, H D, Pocock, S J, Ware, J H, Feit, F, Colombo, A, Aylward, P E, Cequier, A R, Darius, H, Desmet, W, Ebrahimi, R, Harmon, M, Rasmussen, L H, Rupprecht, H-J, Hoekstra, J, Mehran, R & Ohman, E M 2006, ' Bivalirudin for patients with acute coronary syndromes. ' The New England Journal of Medicine, vol. 355, no. 21, pp. 2203-16. .
Flinders University PURE

BACKGROUND: Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight hepa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::428e431a8a81daf7a35da6f3c5152e43
https://doi.org/10.1056/nejmoa062437

Timing of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes—Reply

Autor: Gregg W. Stone, for the ACUITY Investigators

Publikováno v: JAMA. 298:37

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::17e757e008efb6b93c69eed6c92a1e09
https://doi.org/10.1001/jama.298.1.37-b

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.